Stage IIIB Breast Cancer Completed Phase 1 Trials for Fulvestrant (DB00947)

IndicationStatusPhase
DBCOND0028549 (Stage IIIB Breast Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02219789Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by SurgeryTreatment